No. | Strategy | Sites N (%) | Correlation | P value |
---|---|---|---|---|
In FY15 did your center use any of these infrastructure changes to promote HCV care in your center? | ||||
1 | Change physical structure and equipment (e.g., purchase a FibroScan, expand clinic space, open new clinics) | 42 (53) | 0.36 | <0.01 |
2 | Change the record systems (e.g., locally create new or update to national clinical reminder in CPRS, develop standardized note templates) | 57 (71) | −0.02 | 0.89 |
3 | Change the location of clinical service sites (e.g., extend HCV care to the CBOCs) | 21 (26) | 0.36 | <0.01 |
4 | Develop a separate organization or group responsible for disseminating HCV care (outside of the HIT Collaborative) | 18 (23) | 0.21 | 0.07 |
5 | Mandate changes to HCV care (e.g., when you changed to the new HCV medications was this based on a leadership mandate?) | 44 (55) | 0.05 | 0.69 |
6 | Create or change credentialing and/or licensure standards (e.g., change scopes of practice or service agreements) | 23 (29) | 0.01 | 0.92 |
7 | Participate in liability reform efforts that make clinicians more willing to deliver the clinical innovation | 3 (4) | 0.23 | 0.04 |
8 | Change accreditation or membership requirements | 3 (4) | 0.23 | 0.04 |
In FY15 did your center use any of these financial strategies to promote HCV care in your center? | ||||
9 | Access new funding (This DOES NOT include funding from national VA for the medications, but should include receiving funds from the HIT Collaborative to your center) | 24 (30) | 0.20 | 0.08 |
10 | Alter incentive/allowance structures | 4 (5) | 0.04 | 0.76 |
11 | Provide financial disincentives for failure to implement or use the clinical innovations | 0 | . | . |
12 | Respond to proposals to deliver HCV care (e.g., submit a HIT proposal to obtain money for your center specifically) | 35 (44) | 0.19 | 0.11 |
13 | Change billing (e.g., create new clinic codes for billing for HCV treatment or HCV education) | 9 (11) | 0.17 | 0.15 |
14 | Place HCV medications on the formulary | 56 (70) | −0.05 | 0.67 |
15 | Alter patient fees | 0 | ||
16 | Use capitated payments | 0 | ||
17 | Use other payment schemes | 4 (5) | 0.22 | 0.06 |
18 | Create new clinical teams (e.g., interdisciplinary clinical working groups) | 37 (46) | 0.25 | 0.04 |
19 | Facilitate the relay of clinical data to providers (e.g., provide outcome data to providers) | 45 (56) | 0.20 | 0.09 |
20 | Revise professional roles (e.g., allow the pharmacist to see and treat patients in the clinic) | 57 (71) | 0.24 | 0.04 |
21 | Develop reminder systems for clinicians (e.g., use CPRS reminders) | 27 (34) | −0.16 | 0.19 |
22 | Develop resource sharing agreements (e.g., partner with the VERC, the HITs, or other organizations with the resources to help implement changes) | 21 (26) | 0.24 | 0.04 |
In FY15 did your center employ any of these activities to provide interactive assistance to promote HCV care in your center? | ||||
23 | Use outside assistance often called “facilitation” (e.g., coaching, education, and/or feedback from the facilitator) | 6 (8) | 0.16 | 0.17 |
24 | Have someone from inside the clinic or center (often called “local technical assistance”) tasked with assisting the clinic | 12 (15) | 0.38 | <0.01 |
25 | Provide clinical supervision (e.g., train providers) | 35 (44) | 0.29 | 0.01 |
26 | Use a centralized system (i.e., from the VISN) to deliver facilitation | 22 (28) | 0.38 | <0.01 |
In FY15 did your center employ any of these activities to tailor HCV care in your center? | ||||
27 | Use data experts to manage HCV data (e.g., use the VERC, pharmacy benefits management, VISN, or CCR data experts to track patients or promote care) | 46 (58) | 0.18 | 0.12 |
28 | Use data warehousing techniques (e.g., dashboard, clinical case registry, CDW) | 68 (85) | 0.15 | 0.19 |
29 | Tailor strategies to deliver HCV care (i.e., alter HCV care to address barriers to care that you identified in your population using data you collected) | 50 (63) | 0.21 | 0.08 |
30 | Promote adaptability (i.e., Identify the ways HCV care can be tailored to meet local needs and clarify which elements of care must be maintained to preserve fidelity) | 44 (55) | 0.16 | 0.17 |
In FY15 did your center employ any of these activities to train or educate providers to promote HCV care in your center? | ||||
31 | Conduct educational meetings | 41 (51) | 0.24 | 0.05 |
32 | Have an expert in HCV care meet with providers to educate them | 33 (41) | 0.34 | <0.01 |
33 | Provide ongoing HCV training | 39 (49) | 0.26 | 0.03 |
34 | Facilitate the formation of groups of providers and fostered a collaborative learning environment | 35 (44) | 0.38 | <0.01 |
35 | Developed formal educational materials | 31 (39) | 0.00 | 0.97 |
36 | Distribute educational materials (e.g., guidelines, manuals, or toolkits) | 44 (55) | 0.11 | 0.35 |
37 | Provide ongoing consultation with one or more HCV treatment experts | 46 (58) | 0.11 | 0.37 |
38 | Train designated clinicians to train others (e.g., primary care providers, SCAN-ECHO) | 16 (20) | −0.07 | 0.56 |
39 | Vary the information delivery methods to cater to different learning styles when presenting new information | 29 (36) | 0.29 | 0.02 |
40 | Give providers opportunities to shadow other experts in HCV | 26 (33) | 0.12 | 0.32 |
41 | Use educational institutions to train clinicians | 9 (11) | 0.21 | 0.07 |
In FY15 did your center employ any of these activities to develop stakeholder interrelationships to promote HCV care in your center? | ||||
42 | Build a local coalition/team to address challenges | 42 (53) | 0.27 | 0.03 |
43 | Conduct local consensus discussions (i.e., determine how to change things by having meetings with local leaders and providers) | 38 (48) | 0.42 | <0.01 |
44 | Obtain formal written commitments from key partners that state what they will do to implement HCV care (e.g., written agreements with CBOCS) | 3 (4) | 0.20 | 0.09 |
45 | Recruit, designate, and/or train leaders | 21 (26) | 0.29 | 0.01 |
46 | Inform local opinion leaders about advances in HCV care | 39 (49) | 0.33 | <0.01 |
47 | Share the knowledge gained from quality improvement efforts with other sites outside your medical center | 30 (38) | 0.32 | <0.01 |
48 | Identify and prepare champions (i.e., select key individuals who will dedicate themselves to promoting HCV care) | 40 (50) | 0.29 | 0.01 |
49 | Organize support teams of clinicians who are caring for patients with HCV and given them time to share the lessons learned and support one another’s learning | 21 (26) | 0.16 | 0.18 |
50 | Use advisory boards and interdisciplinary workgroups to provide input into HCV policies and elicit recommendations | 21 (26) | 0.09 | 0.46 |
51 | Seek the guidance of experts in implementation | 35 (44) | −0.01 | 0.92 |
52 | Build on existing high-quality working relationships and networks to promote information sharing and problem solving related to implementing HCV care | 49 (61) | 0.24 | 0.04 |
53 | Use modeling or simulated change | 10 (13) | 0.25 | 0.04 |
54 | Partner with a university to share ideas | 11 (14) | 0.27 | 0.02 |
55 | Make efforts to identify early adopters to learn from their experiences | 13 (16) | 0.32 | <0.01 |
56 | Visit other sites outside your medical center to try to learn from their experiences | 12 (15) | 0.30 | 0.01 |
57 | Develop an implementation glossary | 2 (3) | 0.17 | 0.15 |
58 | Involve executive boards | 18 (23) | 0.15 | 0.21 |
In FY15 did your center employ any of these evaluative and iterative strategies to promote HCV care in your center? | 2 (3) | |||
59 | Assess for readiness and identify barriers and facilitators to change (e.g., administer the organizational readiness to change survey) | 21 (26) | 0.16 | 0.20 |
60 | Conduct a local needs assessment (i.e., collect data to determine how best to change things) | 36 (45) | 0.12 | 0.31 |
61 | Develop a formal implementation blueprint (i.e., make a written plan of goals and strategies) | 27 (34) | 0.11 | 0.37 |
62 | Start with small pilot studies and then scale them up | 18 (23) | 0.08 | 0.50 |
63 | Collect and summarize clinical performance data and give it to clinicians and administrators to implement changes in a cyclical fashion using small tests of change before making system-wide changes | 17 (21) | 0.25 | 0.04 |
64 | Conduct small tests of change, measured outcomes, and then refined these tests | 15 (19) | 0.11 | 0.36 |
65 | Develop and use tools for quality monitoring (this includes standards, protocols and measures to monitor quality) | 33 (41) | 0.07 | 0.56 |
66 | Develop and organize systems that monitor clinical processes and/or outcomes for the purpose of quality assurance and improvement (i.e., create an overall system for monitoring quality--not just tools to use in quality monitoring, which is addressed in the last item) | 24 (30) | 0.18 | 0.14 |
67 | Intentionally examine the efforts to promote HCV care | 49 (61) | 0.08 | 0.49 |
68 | Develop strategies to obtain and use patient and family feedback | 16 (20) | −0.11 | 0.35 |
In FY15 did your center employ any of these strategies to engage patient consumers to promote HCV care in your center? | ||||
69 | Involve patients/consumers and family members | 40 (50) | 0.01 | 0.91 |
70 | Engage in efforts to prepare patients to be active participants in HCV care (e.g., conduct education sessions to teach patients about what questions to ask about HCV treatment) | 50 (63) | 0.39 | <0.01 |
71 | Intervene with patients/consumers to promote uptake and adherence to HCV treatment | 57 (71) | 0.08 | 0.51 |
72 | Use mass media (e.g., local public service announcements; magazines like VANGUARD, newsletters, online/social media outlets) to reach large numbers of people | 14 (18) | 0.00 | 0.98 |
73 | Promote demand for HCV care among patients through any other means | 32 (40) | 0.19 | 0.12 |